RBC Capital initiates Insmed with an Outperform rating, citing brensocatib’s launch potential and Arikayce’s growth. FDA decision on brensocatib due August 2025.
Latest Ratings for INSM
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | SVB Leerink | Maintains | Outperform | |
| Dec 2021 | JP Morgan | Initiates Coverage On | Overweight | |
| Oct 2021 | Cantor Fitzgerald | Initiates Coverage On | Overweight |
